Marpai, Inc. (MRAI) Stock Competitors & Peer Comparison
See (MRAI) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Healthcare Plans Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| MRAI | $0.53 | -5.36% | 9.2M | -0.09 | -$6.16 | N/A |
| UNH | $413.00 | +1.58% | 374.8B | 31.06 | $13.29 | +2.15% |
| CVS | $97.06 | -0.02% | 123.8B | 42.56 | $2.28 | +2.74% |
| ANTM | $482.58 | +2.71% | 114.6B | 18.99 | $25.41 | +1.00% |
| ELV | $424.43 | +1.50% | 92.2B | 17.99 | $23.60 | +1.61% |
| CI | $295.00 | +1.86% | 78B | 2.59 | $113.71 | +2.09% |
| HUM | $363.18 | +2.02% | 43.6B | 38.79 | $9.36 | +0.97% |
| CNC | $66.21 | +1.81% | 32.7B | -5.07 | -$13.05 | N/A |
| MOH | $203.06 | +2.34% | 10.6B | 54.58 | $3.72 | N/A |
| OSCR | $27.22 | -0.62% | 7.1B | -50.41 | -$0.54 | N/A |
Stock Comparison
MRAI vs UNH Comparison June 2026
MRAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRAI stands at 9.2M. In comparison, UNH has a market cap of 374.8B. Regarding current trading prices, MRAI is priced at $0.53, while UNH trades at $413.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRAI currently has a P/E ratio of -0.09, whereas UNH's P/E ratio is 31.06. In terms of profitability, MRAI's ROE is +0.50%, compared to UNH's ROE of +0.12%. Regarding short-term risk, MRAI is more volatile compared to UNH. This indicates potentially higher risk in terms of short-term price fluctuations for MRAI.Check UNH's competition here
MRAI vs CVS Comparison June 2026
MRAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRAI stands at 9.2M. In comparison, CVS has a market cap of 123.8B. Regarding current trading prices, MRAI is priced at $0.53, while CVS trades at $97.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRAI currently has a P/E ratio of -0.09, whereas CVS's P/E ratio is 42.56. In terms of profitability, MRAI's ROE is +0.50%, compared to CVS's ROE of +0.04%. Regarding short-term risk, MRAI is more volatile compared to CVS. This indicates potentially higher risk in terms of short-term price fluctuations for MRAI.Check CVS's competition here
MRAI vs ANTM Comparison June 2026
MRAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRAI stands at 9.2M. In comparison, ANTM has a market cap of 114.6B. Regarding current trading prices, MRAI is priced at $0.53, while ANTM trades at $482.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRAI currently has a P/E ratio of -0.09, whereas ANTM's P/E ratio is 18.99. In terms of profitability, MRAI's ROE is +0.50%, compared to ANTM's ROE of +0.12%. Regarding short-term risk, MRAI is less volatile compared to ANTM. This indicates potentially lower risk in terms of short-term price fluctuations for MRAI.Check ANTM's competition here
MRAI vs ELV Comparison June 2026
MRAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRAI stands at 9.2M. In comparison, ELV has a market cap of 92.2B. Regarding current trading prices, MRAI is priced at $0.53, while ELV trades at $424.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRAI currently has a P/E ratio of -0.09, whereas ELV's P/E ratio is 17.99. In terms of profitability, MRAI's ROE is +0.50%, compared to ELV's ROE of +0.12%. Regarding short-term risk, MRAI is less volatile compared to ELV. This indicates potentially lower risk in terms of short-term price fluctuations for MRAI.Check ELV's competition here
MRAI vs CI Comparison June 2026
MRAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRAI stands at 9.2M. In comparison, CI has a market cap of 78B. Regarding current trading prices, MRAI is priced at $0.53, while CI trades at $295.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRAI currently has a P/E ratio of -0.09, whereas CI's P/E ratio is 2.59. In terms of profitability, MRAI's ROE is +0.50%, compared to CI's ROE of +0.15%. Regarding short-term risk, MRAI is less volatile compared to CI. This indicates potentially lower risk in terms of short-term price fluctuations for MRAI.Check CI's competition here
MRAI vs HUM Comparison June 2026
MRAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRAI stands at 9.2M. In comparison, HUM has a market cap of 43.6B. Regarding current trading prices, MRAI is priced at $0.53, while HUM trades at $363.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRAI currently has a P/E ratio of -0.09, whereas HUM's P/E ratio is 38.79. In terms of profitability, MRAI's ROE is +0.50%, compared to HUM's ROE of +0.06%. Regarding short-term risk, MRAI is less volatile compared to HUM. This indicates potentially lower risk in terms of short-term price fluctuations for MRAI.Check HUM's competition here
MRAI vs CNC Comparison June 2026
MRAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRAI stands at 9.2M. In comparison, CNC has a market cap of 32.7B. Regarding current trading prices, MRAI is priced at $0.53, while CNC trades at $66.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRAI currently has a P/E ratio of -0.09, whereas CNC's P/E ratio is -5.07. In terms of profitability, MRAI's ROE is +0.50%, compared to CNC's ROE of -0.29%. Regarding short-term risk, MRAI is less volatile compared to CNC. This indicates potentially lower risk in terms of short-term price fluctuations for MRAI.Check CNC's competition here
MRAI vs MOH Comparison June 2026
MRAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRAI stands at 9.2M. In comparison, MOH has a market cap of 10.6B. Regarding current trading prices, MRAI is priced at $0.53, while MOH trades at $203.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRAI currently has a P/E ratio of -0.09, whereas MOH's P/E ratio is 54.58. In terms of profitability, MRAI's ROE is +0.50%, compared to MOH's ROE of +0.04%. Regarding short-term risk, MRAI is less volatile compared to MOH. This indicates potentially lower risk in terms of short-term price fluctuations for MRAI.Check MOH's competition here
MRAI vs OSCR Comparison June 2026
MRAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRAI stands at 9.2M. In comparison, OSCR has a market cap of 7.1B. Regarding current trading prices, MRAI is priced at $0.53, while OSCR trades at $27.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRAI currently has a P/E ratio of -0.09, whereas OSCR's P/E ratio is -50.41. In terms of profitability, MRAI's ROE is +0.50%, compared to OSCR's ROE of -0.03%. Regarding short-term risk, MRAI is less volatile compared to OSCR. This indicates potentially lower risk in terms of short-term price fluctuations for MRAI.Check OSCR's competition here
MRAI vs ALHC Comparison June 2026
MRAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRAI stands at 9.2M. In comparison, ALHC has a market cap of 4B. Regarding current trading prices, MRAI is priced at $0.53, while ALHC trades at $19.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRAI currently has a P/E ratio of -0.09, whereas ALHC's P/E ratio is 192.00. In terms of profitability, MRAI's ROE is +0.50%, compared to ALHC's ROE of +0.11%. Regarding short-term risk, MRAI is less volatile compared to ALHC. This indicates potentially lower risk in terms of short-term price fluctuations for MRAI.Check ALHC's competition here
MRAI vs CLOV Comparison June 2026
MRAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRAI stands at 9.2M. In comparison, CLOV has a market cap of 2.2B. Regarding current trading prices, MRAI is priced at $0.53, while CLOV trades at $4.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRAI currently has a P/E ratio of -0.09, whereas CLOV's P/E ratio is -35.75. In terms of profitability, MRAI's ROE is +0.50%, compared to CLOV's ROE of -0.17%. Regarding short-term risk, MRAI is less volatile compared to CLOV. This indicates potentially lower risk in terms of short-term price fluctuations for MRAI.Check CLOV's competition here
MRAI vs BHG Comparison June 2026
MRAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRAI stands at 9.2M. In comparison, BHG has a market cap of 130.5M. Regarding current trading prices, MRAI is priced at $0.53, while BHG trades at $16.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRAI currently has a P/E ratio of -0.09, whereas BHG's P/E ratio is -0.12. In terms of profitability, MRAI's ROE is +0.50%, compared to BHG's ROE of -0.70%. Regarding short-term risk, MRAI is less volatile compared to BHG. This indicates potentially lower risk in terms of short-term price fluctuations for MRAI.Check BHG's competition here
MRAI vs CABR Comparison June 2026
MRAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRAI stands at 9.2M. In comparison, CABR has a market cap of 18M. Regarding current trading prices, MRAI is priced at $0.53, while CABR trades at $1.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRAI currently has a P/E ratio of -0.09, whereas CABR's P/E ratio is -1.77. In terms of profitability, MRAI's ROE is +0.50%, compared to CABR's ROE of -3.00%. Regarding short-term risk, MRAI is less volatile compared to CABR. This indicates potentially lower risk in terms of short-term price fluctuations for MRAI.Check CABR's competition here
MRAI vs BMGL Comparison June 2026
MRAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRAI stands at 9.2M. In comparison, BMGL has a market cap of 12M. Regarding current trading prices, MRAI is priced at $0.53, while BMGL trades at $0.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRAI currently has a P/E ratio of -0.09, whereas BMGL's P/E ratio is -1.45. In terms of profitability, MRAI's ROE is +0.50%, compared to BMGL's ROE of -1.95%. Regarding short-term risk, MRAI is less volatile compared to BMGL. This indicates potentially lower risk in terms of short-term price fluctuations for MRAI.Check BMGL's competition here
MRAI vs GTS Comparison June 2026
MRAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRAI stands at 9.2M. In comparison, GTS has a market cap of 0. Regarding current trading prices, MRAI is priced at $0.53, while GTS trades at $35.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRAI currently has a P/E ratio of -0.09, whereas GTS's P/E ratio is 10.41. In terms of profitability, MRAI's ROE is +0.50%, compared to GTS's ROE of +0.07%. Regarding short-term risk, MRAI is more volatile compared to GTS. This indicates potentially higher risk in terms of short-term price fluctuations for MRAI.Check GTS's competition here
MRAI vs AET Comparison June 2026
MRAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRAI stands at 9.2M. In comparison, AET has a market cap of 0. Regarding current trading prices, MRAI is priced at $0.53, while AET trades at $106.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRAI currently has a P/E ratio of -0.09, whereas AET's P/E ratio is N/A. In terms of profitability, MRAI's ROE is +0.50%, compared to AET's ROE of +0.11%. Regarding short-term risk, MRAI is more volatile compared to AET. This indicates potentially higher risk in terms of short-term price fluctuations for MRAI.Check AET's competition here
MRAI vs MGLN Comparison June 2026
MRAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRAI stands at 9.2M. In comparison, MGLN has a market cap of 0. Regarding current trading prices, MRAI is priced at $0.53, while MGLN trades at $94.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRAI currently has a P/E ratio of -0.09, whereas MGLN's P/E ratio is 8.49. In terms of profitability, MRAI's ROE is +0.50%, compared to MGLN's ROE of +0.00%. Regarding short-term risk, MRAI is more volatile compared to MGLN. This indicates potentially higher risk in terms of short-term price fluctuations for MRAI.Check MGLN's competition here
MRAI vs UAM Comparison June 2026
MRAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRAI stands at 9.2M. In comparison, UAM has a market cap of 0. Regarding current trading prices, MRAI is priced at $0.53, while UAM trades at $1.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRAI currently has a P/E ratio of -0.09, whereas UAM's P/E ratio is N/A. In terms of profitability, MRAI's ROE is +0.50%, compared to UAM's ROE of +0.17%. Regarding short-term risk, MRAI is more volatile compared to UAM. This indicates potentially higher risk in terms of short-term price fluctuations for MRAI.Check UAM's competition here